Apolipoprotein(a) Isoforms and the Risk of Vascular Disease. Systematic Review of 40 Studies Involving 58,000 Participants

Journal of the American College of Cardiology

Volumn 55, Issue 19, 2010, Pages 2160-2167

  Erqou, Sebhat ^a   Thompson, Alexander ^a   Di Angelantonio, Emanuele ^a   Saleheen, Danish ^a   Kaptoge, Stephen ^a   Marcovina, Santica ^b   Danesh, John ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

apolipoprotein(a) isoforms; cardiovascular disease; epidemiology; lipoprotein(a); meta analysis

Indexed keywords

APOLIPOPROTEIN A; ISOPROTEIN;

ANALYTIC METHOD; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; HUMAN; MOLECULAR WEIGHT; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; PUBLICATION; RISK FACTOR; SYSTEMATIC REVIEW; VASCULAR DISEASE;

APOPROTEIN(A); BIOLOGICAL MARKERS; HUMANS; MOLECULAR WEIGHT; PARTICLE SIZE; PROTEIN ISOFORMS; RISK FACTORS; VASCULAR DISEASES;

EID: 77951637599     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.10.080     Document Type: Article

References (66)

1. Marcovina S.M., and Koschinsky M.L. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 82 (1998) 57U-66U
2. McLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330 (1987) 132-137
3. The Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA 302 (2009) 412-423
4. Clarke R., Peden J.F., Hopewell J.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361 (2009) 2518-2528
5. Boerwinkle E., Leffert C.C., Lin J., et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 90 (1992) 52-60
6. Mooser V., Scheer D., Marcovina S.M., et al. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am J Hum Genet 61 (1997) 402-417
7. Boomsma D.I., Knijff P., Kaptein A., et al. The effect of apolipoprotein(a)-, apolipoprotein E-, and apolipoprotein A4- polymorphisms on quantitative lipoprotein(a) concentrations. Twin Res 3 (2000) 152-158
8. Tregouet D.A., Konig I.R., Erdmann J., et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41 (2009) 283-285
9. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301 (2009) 2331-2339
10. Scanu A.M. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. Curr Atheroscler Rep 5 (2003) 106-113
11. Tsimikas S., and Witztum J.L. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 19 (2008) 369-377
12. Simo J.M., Joven J., Vilella E., et al. Impact of apolipoprotein(a) isoform size heterogeneity on the lysine binding function of lipoprotein(a) in early onset coronary artery disease. Thromb Haemost 85 (2001) 412-417
13. Tsimikas S., Clopton P., Brilakis E.S., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 119 (2009) 1711-1719
14. Zeljkovic A., Bogavac-Stanojevic N., Jelic-Ivanovic Z., et al. Combined effects of small apolipoprotein (a) isoforms and small, dense LDL on coronary artery disease risk. Arch Med Res 40 (2009) 29-35
15. Tsimikas S., Tsironis L.D., and Tselepis A.D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 27 (2007) 2094-2099
16. Hobbs H.H., and White A.L. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 10 (1999) 225-236
17. Boffa M.B., Marcovina S.M., and Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 37 (2004) 333-343
18. Scanu A.M., Lawn R.M., and Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 115 (1991) 209-218
19. Martin S., Pedro-Botet J., Joven J., et al. Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart disease. J Lab Clin Med 139 (2002) 181-187
20. Gazzaruso C., Buscaglia P., Garzaniti A., et al. Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension. J Cardiovasc Risk 3 (1996) 191-197
21. Brazier L., Tiret L., Luc G., et al. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. Atherosclerosis 144 (1999) 323-333
22. Holmer S.R., Hengstenberg C., Kraft H.G., et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 107 (2003) 696-701
23. Kraft H.G., Lingenhel A., Kochl S., et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 16 (1996) 713-719
24. Marcovina S.M., Albers J.J., Wijsman E., et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 37 (1996) 2569-2585
25. Kraft H.G., Lingenhel A., Pang R.W., et al. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet 4 (1996) 74-87
26. Kraft H.G., Kochl S., Menzel H.J., et al. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 90 (1992) 220-230
27. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
28. Egger M., Davey S.G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
29. Gazzaruso C., Garzaniti A., Buscaglia P., et al. Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. J Cardiovasc Risk 5 (1998) 37-42
30. Klausen I.C., Sjol A., Hansen P.S., et al. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis 132 (1997) 77-84
31. Parlavecchia M., Pancaldi A., Taramelli R., et al. Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men < 55 years of age. Am J Cardiol 74 (1994) 346-351
32. Calmarza P., Cordero J., Santos V., et al. Apolipoprotein(a) isoforms in infarcted men under 60 years old. Clin Biochem 37 (2004) 911-918
33. Akanji A.O. Apo(a) isoforms do not predict risk for coronary heart disease in a Gulf Arab population. Ann Clin Biochem 37 (2000) 360-366
34. Katsouras C.S., Karabina S.A., Tambaki A.P., et al. Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease. J Cardiovasc Risk 8 (2001) 311-317
35. Emanuele E., Peros E., Minoretti P., et al. Apolipoprotein(a) size polymorphism is associated with coronary heart disease in polygenic hypercholesterolemia. Nutr Metab Cardiovasc Dis 14 (2004) 193-199
36. Rifai N., Ma J., Sacks F.M., et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem 50 (2004) 1364-1371
37. Emanuele E., Peros E., Minoretti P., et al. Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation. Clin Chim Acta 350 (2004) 159-165
38. Zorio E., Falco C., Arnau M.A., et al. Lipoprotein (a) in young individuals as a marker of the presence of ischemic heart disease and the severity of coronary lesions. Haematologica 91 (2006) 562-565
39. Kalina A., Csaszar A., Fust G., et al. The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA)(n) polymorphism with coronary heart disease. Clin Chim Acta 309 (2001) 45-51
40. Bigot E., Robert B., Bard J.M., et al. Lipoprotein (a) phenotype distribution in a population of bypass patients and its influence on lipoprotein (a) concentration. Clin Chim Acta 265 (1997) 99-111
41. Paultre F., Pearson T.A., Weil H.F., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20 (2000) 2619-2624
42. Gazzaruso C., Garzaniti A., Falcone C., et al. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in type 2 diabetic patients and in non-diabetic subjects. Diabet Med 18 (2001) 589-594
43. Gazzaruso C., Garzaniti A., Buscaglia P., et al. Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol 33 (1999) 157-163
44. Kark J.D., Sandholzer C., Friedlander Y., et al. Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis 98 (1993) 139-151
45. Emanuele E., Peros E., Minoretti P., et al. Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects. BMC Cardiovasc Disord 3 (2003) 12
46. Sandholzer C., Saha N., Kark J.D., et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12 (1992) 1214-1226
47. Qin S., Wang S., and Li C. Apolipoprotein (a) polymorphism in relation to coronary heart disease in Chinese Han nationality. Zhonghua Yi Xue Za Zhi 75 (1995) 588
48. Sandholzer C., Boerwinkle E., Saha N., Tong M.C., and Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 89 (1992) 1040-1046
49. Abe A., and Noma A. Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population. Atherosclerosis 96 (1992) 1-8
50. Abe A., Noma A., Lee Y.J., et al. Studies on apolipoprotein(a) phenotypes. Part 2. Phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiographically defined coronary artery diseases. Atherosclerosis 96 (1992) 9-15
51. Geethanjali F.S., Jose V.J., and Kanagasabapathy A.S. Lipoprotein (a) phenotypes in south Indian patients with coronary artery disease. Indian Heart J 54 (2002) 50-53
52. Geethanjali F.S., Luthra K., Lingenhel A., et al. Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. Atherosclerosis 169 (2003) 121-130
53. Gambhir J.K., Kaur H., Prabhu K.M., et al. Association between lipoprotein(a) levels, apo(a) isoforms and family history of premature CAD in young Asian Indians. Clin Biochem 41 (2008) 453-458
54. Yingdong Z., and Xiuling L. Apolipoprotein(a) and cortical cerebral infarction. Chin Med Sci J 14 (1999) 249-254
55. Kronenberg F., Kronenberg M.F., Kiechl S., et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100 (1999) 1154-1160
56. Peynet J., Beaudeux J.L., Woimant F., et al. Apolipoprotein(a) size polymorphism in young adults with ischemic stroke. Atherosclerosis 142 (1999) 233-239
57. Zambrelli E., Emanuele E., Marcheselli S., et al. Apo(a) size in ischemic stroke: relation with subtype and severity on hospital admission. Neurology 64 (2005) 1366-1370
58. Milionis H.J., Filippatos T.D., Loukas T., et al. Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 187 (2006) 170-176
59. Jurgens G., Taddei-Peters W.C., Koltringer P., et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 26 (1995) 1841-1848
60. Gazzaruso C., Buscaglia P., Garzaniti A., et al. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension. J Hypertens 15 (1997) 227-235
61. Ruiz J., Thillet J., Huby T., et al. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia 37 (1994) 585-591
62. McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192 (2007) 432-437
63. ClinicalTrials.gov. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. http://clinicaltrials.gov/ct2/show/NCT00461630 Accessed July 1, 2009
64. Marcovina S.M., Koschinsky M.L., Albers J.J., et al. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 49 (2003) 1785-1796
65. Lanktree M.B., Anand S.S., Yusuf S., et al. Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. J Lipid Res 50 (2009) 1487-1496
66. Anand S.S., Yusuf S., Vuksan V., et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 356 (2000) 279-284